Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i>-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.

JCO Clin Cancer Inform · 2022 · PMC9225680 · PMID 35649212

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The estimated hazard ratio (HR) for an OS of 0.729 (95% CI, 0.184 to 3.900) from multivariate Cox proportional hazards models showed a favorable trend for pertuzumab and trastuzumab compared with external controls.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.